New perspectives on the actions of sulphonylureas and hyperglycaemic sulphonamides on the pancreatic β-cell

P. R. Flatt, O. Shibier, J. Szecowka, P. O. Berggren

Research output: Contribution to journalArticle

51 Scopus citations

Abstract

Sulphonylureas and the hyperglycaemic sulphonamide diazoxide are commonly employed in the therapy of non-insulin-dependent (Type 2) diabetes mellitus and insulinoma, respectively. Stimulatory effects of sulphonylureas on insulin secretion and the inhibitory action of diazoxide are thought to be primarily mediated through modulation of the activity of ATP-sensitive K+ channels (K+-ATP channels) in the β-cell plasma membrane. Certain sulphonylureas are known to be internalised by the pancreatic B-cell. Recent studies suggest that these drugs and diazoxide can influence insulin secretion from electropermeabilised β-cells in which K+-ATP channels and other plasma membrane ion channels are inoperative. This observation suggests that sulphonylureas and diazoxide interact with intracellular sites in the pancreatic B-cell which are directly involved in the regulation of the final stages of exocytosis.

Original languageEnglish (US)
Pages (from-to)157-162
Number of pages6
JournalDiabete et Metabolisme
Volume20
Issue number2
StatePublished - Dec 1 1994

Keywords

  • diazoxide
  • electropermeabilisation
  • exocytosis
  • insulin secretion
  • pancreatic β-cell
  • sulphonylureas

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Fingerprint Dive into the research topics of 'New perspectives on the actions of sulphonylureas and hyperglycaemic sulphonamides on the pancreatic β-cell'. Together they form a unique fingerprint.

  • Cite this

    Flatt, P. R., Shibier, O., Szecowka, J., & Berggren, P. O. (1994). New perspectives on the actions of sulphonylureas and hyperglycaemic sulphonamides on the pancreatic β-cell. Diabete et Metabolisme, 20(2), 157-162.